Dataset Information


Role of cyclin B1/Cdc2 up-regulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazole.

ABSTRACT: During a normal cell cycle, the transition from G? phase to mitotic phase is triggered by the activation of the cyclin B1-dependent Cdc2 kinase. Here we report our finding that treatment of MCF-7 human breast cancer cells with nocodazole, a prototypic microtubule inhibitor, results in strong up-regulation of cyclin B1 and Cdc2 levels, and their increases are required for the development of mitotic prometaphase arrest and characteristic phenotypes.It was observed that there was a time-dependent early increase in cyclin B1 and Cdc2 protein levels (peaking between 12 and 24 h post treatment), and their levels started to decline after the initial increase. This early up-regulation of cyclin B1 and Cdc2 closely matched in timing the nocodazole-induced mitotic prometaphase arrest. Selective knockdown of cyclin B1or Cdc2 each abrogated nocodazole-induced accumulation of prometaphase cells. The nocodazole-induced prometaphase arrest was also abrogated by pre-treatment of cells with roscovitine, an inhibitor of cyclin-dependent kinases, or with cycloheximide, a protein synthesis inhibitor that was found to suppress cyclin B1 and Cdc2 up-regulation. In addition, we found that MAD2 knockdown abrogated nocodazole-induced accumulation of cyclin B1 and Cdc2 proteins, which was accompanied by an attenuation of nocodazole-induced prometaphase arrest.These observations demonstrate that the strong early up-regulation of cyclin B1 and Cdc2 contributes critically to the rapid and selective accumulation of prometaphase-arrested cells, a phenomenon associated with exposure to microtubule inhibitors.


PROVIDER: S-EPMC3168870 | BioStudies | 2011-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3777406 | BioStudies
2018-01-01 | S-EPMC5938023 | BioStudies
1000-01-01 | S-EPMC1190358 | BioStudies
1000-01-01 | S-EPMC3055189 | BioStudies
1000-01-01 | S-EPMC2771089 | BioStudies
2016-01-01 | S-EPMC5037805 | BioStudies
1000-01-01 | S-EPMC5253641 | BioStudies
1000-01-01 | S-EPMC2906566 | BioStudies
1000-01-01 | S-EPMC5650293 | BioStudies
2003-01-01 | S-EPMC206994 | BioStudies